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A 51-year-old man, who was diagnosed with Fabry disease resulting from a kidney biopsy
for proteinuria and renal failure in 2002, was admitted to our hospital for sustained ventricular
tachycardia (VT). In the electrophysiological study, VT (cycle length: 310ms) was
successfully induced by right ventricle programmed stimulation and the twelve-lead
electrocardiogram showed a right bundle branch block conﬁguration with right axis deviation.
The mechanism of the VT was considered to be reentry by entrainment phenomenon. An
electro-anatomical mapping system identiﬁed a low voltage area located close to the left
ventricular anterior-apical wall. During VT an isolated pre-potential was recorded 42ms prior
to the QRS onset near the border zone which was located between the low and normal voltage
areas. At this mapping site entrainment with fusion and a post-pacing interval that matched
the VT cycle length were observed. A radiofrequency energy delivery at this site terminated
the VT after 35 seconds. The entrainment mapping could be useful for identifying a critical
reentry circuit path. This case is the ﬁrst description of reentrant VT originating from the
thickened left ventricle wall in a patient with Fabry disease.
(J Arrhythmia 2010; 26: 209–215)
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Introduction
Fabry disease (an alpha galactosidase A deﬁcien-
cy) is an X-linked hereditary disorder leading to the
pathological accumulation of globotriaosylceramide
(GL-3) in lysosomes, particularly in the vascular
endothelium of the kidney, heart and brain. Recent
data suggest that 60% of Fabry disease patients have
cardiac symptoms, including palpitation and syn-
cope; however, patients with sustained ventricular
tachycardia (VT) are rare.1) We report a case of
Fabry disease with sustained reentrant VT. In this
case, the VT reentry circuit could be identiﬁed by
entrainment mapping and an electro-anatomical
mapping (CARTO) during electrophysiological
study (EPS). The VT terminated with radiofrequency
(RF) ablation. To the best of our knowledge, this
report describes for the ﬁrst time VT that originates
from a thickened left ventricular (LV) wall that is
based on a reentrant mechanism.
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Case report
A 51-year-old man presented to our hospital with
palpitations. His mother and uncle (mother’s young-
er brother) had Fabry disease and died of renal
failure. In 1993, the results of a health checkup
indicated he had electrocardiographic abnormalities,
ventricular hypertrophy and proteinuria. In 2002, he
was diagnosed as having Fabry disease based on his
family history, the enzyme activity, and the results of
a kidney biopsy and genetic evaluation. Enzyme
replacement therapy (ERT; agalsidase beta,
Fabrazyme 1mg/Kg every two weeks) with -
GAL A was initiated in May of 2004. As he had no
cardiac symptoms except for LV hypertrophy, he
annually underwent electrocardiography (ECG) and
echocardiography. However, he started to complain
of short-lasting palpitations in March of 2007 and
their frequency gradually increased. On the 20th of
September, 2007, he was transferred to our hospital
by ambulance with sustained palpitations. On arrival,
his conscious level was clear and blood pressure was
102/60mmHg. The ECG on admission revealed
sustained VT, with a right bundle branch block
conﬁguration, right axis deviation, inferior axis, and
a heart rate of 194 bpm (Figure 1A). Intravenous
lidocaine of 100mg restored sinus rhythm, however
the eﬀect was transiently. He was admitted to our
hospital for treatment of VT. The signal-averaged
ECG showed positive ventricular late potentials prior
to administering any anti-arrhythmic drugs. M-
mode, 2-dimensional, and doppler echocardiography
were performed. The patient showed a normal
ejection fraction (EF) (68%). End-diastolic thickness
of the posterior wall was 11.0mm, and maximal LV
wall thickness was 20.5mm in the septal area. There
was no dilatation of the LV (LVDd = 50mm,
LVDs = 31mm). Figures 1B and 1C show the mag-
netic resonance image (MRI). A gradient-echo MRI
revealed a remarkably thickened LV septal wall and
thinned LV apex (Figure 1B). Furthermore, a T2-
weighted MRI scan revealed an area with a partially
high signal intensity in the basal epicardium and
antero-septal endocardium, which suggested there
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Figure 1
A) Clinical ventricular tachycardia (VT) morphology on admission
B) Magnetic Resonance Image (MRI): gradient echo sequence
C) MRI: T2-weighted image
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was ischemia, edema or myocardial degeneration
(Figure 1C). After written informed consent was
obtained from the patient and his family, several
catheterization studies were performed. Coronary
angiography revealed no signiﬁcant stenosis. Right
ventricle (RV) endomyocardial biopsy specimens,
which were stained with hematoxylin and eosin,
exhibited diﬀuse sarcoplasmic vacuolar degenera-
tion. An electron microscope image identiﬁed typical
lysosomal inclusions with a concentric lamellar
conﬁguration, the so-called Zebra body, in the
myocardial cells. An EPS, endocardial catheter
mapping and RF ablation were performed to clarify
the onset mechanism and eliminate the VT. Elec-
trode catheters (AF Division, St. Jude Medical,
Minnesota, MN, USA) were inserted from the
femoral vein into the right ventricular (RV) apex,
right atrium (5-Fr. 5 pole catheter) and His bundle
region (5-Fr. 6 pole catheter). A CardioLab (General
Electric Company, Schenectady, NY, USA) was
used to record the 12-lead body surface ECG and
intracardiac electrograms at 100 to 200mm/sec.
Classic entrainment criteria, including constant
fusion and progressive fusion, were demonstrated
by rapid pacing from the RV apex during the VT,
suggesting that the mechanism of VT was reentry
with an excitable gap (Figure 3A).
Induced VT cycle length ranged from 290ms to
310ms and it remains possible that VT changed to
become hemodynamically unstable. Pace mapping
was used to deﬁne potential exit sites along the
border of low-voltage region in the LV anterior-
apical wall. A perfect pace map could not been
obtained anywhere in the endocardium. Induced
sustained VT by double extra stimulation from the
RV apex was the same QRS morphology as the
clinical arrhythmia. Not only voltage map during
sinus rhythm but also activation map during VT
were constructed using the CARTO system (Bio-
sense Webster Inc., Diamond Bar, CA, USA)
(Figure 2A). A MRI indicated that there was a thin
wall which corresponded to a low voltage area.
RF energy, which was set at 50 Watts, with a
duration of 60 seconds and maximal temperature
of 60 C, was delivered using a 4mm-tip ablation
Navistar catheter (Biosense Webster Inc.) to the sites
where the QRS axis corresponded and was similar to
the pace map (Figure 2A). After 25 RF applications,
VT cycle length was signiﬁcantly prolonged to
340ms and lasted less than 20 seconds by program-
A) First session, 
    Bipolar voltage map
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Figure 2
A) A cranial left anterior oblique (LAO) electro-anatomical mapping bipolar voltage map of the left ventricle
(LV) at ﬁrst session. Voltage is color-coded with the upper voltage threshold set at a commonly employed
normal value of >1:5mV, such that the areas exceeding this amplitude are displayed in purple. The lower
amplitude threshold is set for <0:5mV, such that these areas are red. Radiofrequency (RF) lesions (red tags)
rendered the VT nonsustained and prolonged.
B) LV activation map of VT associated with Fabry disease at second session. Earliest activation is indicated by
red. Cranial right anterior oblique (RAO) views are shown. Diﬀerent map with 202 sites is acquired in a point-
by-point manner during VT. The locations of the VT termination by RF energy delivery are indicated by the
arrow.
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med stimulation reproducibly, therefore the session
was ended.
However, the VT recurred a few days after the
ﬁrst RF ablation. The patient then underwent another
EPS procedure and RF ablation on the 8th hospital
day. During the ﬁrst EPS procedure, a 4mm-tip
ablation catheter was used. However, insuﬃcient RF
energy was delivered to the diseased area due to the
signiﬁcantly thickened myocardium. Therefore, we
used an 8mm-tip ablation catheter for the second
EPS session. The VT induced by RV programmed
stimulation was the same VT morphology and cycle
length as the ﬁrst session and was sustained.
Entrainment mapping could then be performed.
Entrainment mapping was performed around the
site where the QRS axis corresponded to the site of
the RF application sites in the ﬁrst session. Entrain-
ment with fusion was observed in the LV anterior-
apical wall, where the pre-potential preceded the
onset of the QRS complex by 42ms, and the post-
pacing interval (PPI) matched the VT cycle length
(Figure 3B). It was suggested the pacing site was in
an outer loop of the VT reentry circuit. RF energy
was delivered for 35 seconds to that site where the
pre-potential was observed, which successfully ter-
minated the VT. In addition, we ablated the sites
with a total of 50 RF applications around the LV
anterior-apical wall with an RF setting that was the
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Figure 3
A) The entrainment phenomenon during pacing (S) from right ventricular apex at cycle lengths of 305ms, 300ms and 290ms. The
morphology of the QRS complexes represents diﬀerent degrees of ventricular fusion (progressive fusion) during transient entrainment at
the respective pacing rates.
B) Entrainment of VT produced by pacing at an outer loop site in the circuit is shown. The last two stimuli (S) of a stimulus train at a cycle
length of 310ms are shown. Pacing accelerates the QRS complexes to the paced cycle length of 310ms with QRS fusion. Entrainment
with QRS fusion is observed close to the LV anterior-apical wall. Both isolated pre-potentials () and large potentials ( ) are recorded by
the ablation catheter. An isolated pre-potential () preceding the onset of the QRS complex by 42ms was observed. The post pacing
interval is measured to this small potential, which is 337ms and equal to the VT cycle length. Stimulus-QRSn+1 (arrow) is 379ms and the
Egn+2-QRSn+3 is 379ms (arrow). The N + 1 diﬀerence equals the PPI-TCL diﬀerence; both are zero. Measurements using the ABL3-4
Eg as the ﬁducial point are also shown. The S-Vn+1 is 404ms, and the Egn+2-Vn+3 is also 404ms. (see text for discussion)
I, III, aVF, V1: body surface standard leads, RVa: right ventricular apex, ABL1–2: distal pair of electrodes on the ablation catheter,
ABL3–4: proximal pair of electrodes on the ablation catheter, PPI: the post pacing interval, S: stimulus, Eg: electrogram
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same as the ﬁrst session (Figure 2B). Although the
VT was induced by RV extrastimulation, second
session ended because the VT was not sustained and
VT cycle length signiﬁcantly prolonged from 340 to
400ms and lasted less than 5 seconds. This site was
near the border zone which was located between the
low and normal voltage areas in the LV anterior-
apical wall in CARTO voltage map obtained from
the ﬁrst session.
We felt that it would be diﬃcult to completely
eliminate the VT by RF ablation alone. Thus we
initiated an administration of 400mg/day of amio-
darone. After that, the VT cycle length did not
prolong and terminate spontaneously, giving the
appearance of a VT storm, until after the second
sesseion of RF ablation and administration of
amiodarone.
We recommended the implanted cardioverter
deﬁbrillation (ICD) to prevent sudden cardiac death.
However, an ICD could not be implanted because
the patient refused stubbornly and ventricular ﬁbril-
lation could not be induced by burst and triple extra
pacing protocol.
Finally, no episodes of VT have appeared after the
patient left the hospital. Now, the patient remains
under close observation as an outpatient and is being
treated with 100mg/day of amiodarone. So far, VT
has not recurred for two years.
Discussion
Fabry disease is an inherited X-linked lysosomal
storage disease resulting from the deﬁcient activity
of the enzyme -GAL and the accumulation of its
glycolipid substrate, globotriaosylceramide (GL-3),
particularly in the vascular endothelium. Typical
symptoms of this disease are a youth-onset cerebral
infarction, LV hypertrophy, renal dysfunction, ab-
dominal pain, angiokeratoma, hypohidrosis and
burning pain in the extremities. In particular,
exacerbated kidney failure, heart disease or stroke
may lead to an early death.
Nowadays, many cases of cardiac sudden death
in Fabry disease patients have been reported. ERT
with -GAL, which prevents the accumulation of
GL-3, is the only eﬀective treatment for Fabry
disease. ERT also prevents further functional
deterioration of the diseased organs and improves
the impaired function.2–4) It has been recognized
that an early diagnosis of Fabry disease may be
crucial for the patient’s prognosis.5,6) Since 2004,
ERT for Fabry disease has been available in Japan.
In this patient, ERT was continued since May of
2004. We encountered a Fabry disease patient with
sustained VT. Constant and progressive fusion was
conﬁrmed by RV rapid pacing, and the mechanism
of VT was considered to be reentry.7) Entrainment
mapping was performed in the LV endocardium,
but entrainment with concealed fusion could not be
observed in any sites of LV endomyocardium.
Although pacing was performed from various parts
of the endocardium during sinus rhythm, a perfect
pace map could not be observed. We could not
identify any breakthrough points to the endocardial
site. Accordingly, we presumed that the location
of the VT reentry circuit exit might be in the
myocardium. Figure 3B shows the entrainment map-
ping just before the VT termination. During
entrainment from the ablation catheter, entrainment
with QRS fusion was observed. Both isolated pre-
potentials and large potentials are recorded by the
ablation catheter (Figure 3B). An isolated pre-poten-
tial, which preceded the onset of the QRS complex
by 42ms, was recorded at a point, close to the
anterior apical wall during VT. Electrical noise
introduced during pacing obscured the electrograms
at the stimulating ablation catheter electrodes.
Comparing the proximal and distal potentials
recorded by the ablation catheter suggests that the
large potential might also be captured in a localized
electrogram. The post pacing interval (PPI) is
measured to the local pre-potential, which is
337msec and equal to the VT cycle length
(TCL). Furthermore, the N + 1 diﬀerence equaled
the PPI-TCL diﬀerence and was 0 at re-entry
circuit sites in this case.7) This site is consistent
with an outer loop. A pre-potential was probably
the activation at the outer loop very close to the
exit, and the large potential was the activation of
the healthier tissue, just outside of the reentry
circuit. The ablation catheter was considered to be
located just outside of the exit of the reentry circuit
(Figure 4).
RF energy, which might have reached the reentry
circuit exit in the myocardium, successfully termi-
nated the VT. Generally outer loop sites may be in
relatively broad regions of the reentry path, ex-
plaining the low incidence of tachycardia termina-
tion.8,9) But, if an isolated pre-potential is present
at such a site, it increases the likelihood of VT
termination.10) In our case, it is probable that the
outer loop site with a pre-potential is near a
narrower potion of the circuit exit in the myocar-
dium, from which the pre-potential is recorded.
However, the RF energy was not suﬃcient to reach
the deepest part of the diseased area. We believed
that was the reason why the VT circuit was not
completely eliminated.
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Patients with Fabry disease, particularly those
with cardiac Fabry disease, have a high incidence of
cardiac sudden death due to fatal arrhythmias and
heart failure.1) To date, only a handful of studies
have reported Fabry disease patients associated with
sustained VT. Most of them were implanted with
ICD, and to the best of our knowledge, no studies
have reported a successful RF ablation in those using
the CARTO system and entrainment mapping. In the
present case, the arrhythmia was not completely
cured by RF ablation alone; however, a hybrid
therapy with amiodarone along with RF ablation
could successfully control the VT. In general, if
patients with Fabry disease are not treated with ERT,
the cardiac muscle ﬁbers will rapidly degenerate,
which may lead to sudden death due to fatal
arrhythmias or heart failure. In the present case, it
is noteworthy that the VT occurred 4 years after the
ERT had been initiated. Although the patient had
progressive LV hypertrophy, the LV contraction was
maintained and the EPS revealed no ventricular
ﬁbrillation. The ERT could have controlled the
myocardial degeneration; however, how the ERT
aﬀects the reentry mechanism remains unsolved. A
cardiac deﬁbrillator should be implanted in order to
prevent any sudden cardiac death in such cases,
but our patient did not wish to undergo an ICD
implantation. The patient needs to be kept under
close observation in order to decide whether an ICD
is necessary.
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Figure 4
Schema of the VT reentry circuit. The reentry circuit is indicated with black arrows. An ablation catheter is
located close to the reentry circuit exit. Small and large potentials are recorded by the catheter. A small pre
potential () is the local electrogram which is captured with pacing, and considered to be the outer loop
activation very close to the isthmus exit. A large potential ( ) is also captured, and considered to be the
activation of the healthier tissue outside of the reentry exit.
J Arrhythmia Vol 26 No 3 2010
214
6) Linhart A, Magage S, Palecek T, et al: Cardiac involve-
ment in Fabry disease. Acta Paediatr Suppl 2002; 91: 15–
20
7) Kyoko S, Stevenson WG, Maisel WH, et al: The N+1
diﬀerence: Anew measure for entrainment mapping. J
Am Coll Cardiol 2001; 37: 1386–1394
8) Stevenson WG, Khan H, Sager P, et al: Identiﬁcation of
reentry site during catheter mapping and radiofrequency
ablation of ventricular tachycardia late after infarction.
Circulation 1993; 88: 1647–1670
9) Harada T, Aonuma K, Yamauchi Y, et al: Catheter
ablation of ventricular tachycardia in patients with right
ventricular dysplasia: identiﬁcation of target sites by
entrainment mapping technique. PACE 1998; 21: 2547–
2550
10) Kocovic DZ, Harada T, Friedman PL, et al: Charac-
teristics of electrograms recorded at reentry circuit sites
and bystanders during ventricular tachycardia after
myocardial infarction. J Am Coll Cardiol 1999; 34:
381–388
Nakano E Ablation of reentrant ventricular tachycardia in Fabry disease
215
